Company Overview and News

27
Is The Tilray-Sandoz Canada Alliance Worth Getting Excited About?

2018-10-04 seekingalpha - 1
Based on price action, Tilray Inc. (NASDAQ:TLRY) is currently the most exciting name in the very hot Canadian pot stock space. Also based on price action, Novartis AG (NYSE:NVS) is a boring Big Pharma stock. While I have previously warned investors that pot stocks are unlikely to be good buy-and-hold stocks, TLRY seems to have its supporters.
STZ.B ACB GWPH JNJ ACBFF BCNQY NVS STZ CMMDF TLRY GWP SLF

3
Aurora Cannabis: Wow! That Was An Impressive Quarter

2018-09-25 seekingalpha - 1
Aurora Cannabis reported strong fiscal 2018 Q4 results on Monday night and provided a comprehensive corporate update that boosted our confidence in this stock.
ACB ACBFF APHQF CMMDF MEDFF TLRY HMPPF

2
Are We Heading Towards Another Meltdown For Pot Stocks?

2018-09-04 seekingalpha - 1
The recent rally must have brought back some memory of the spectacular rise and fall of the cannabis sector in early 2018.
HMLSF APHQF CMMDF DEO TLRY

5
Aurora Cannabis: Why Acquiring MedReleaf Was An Upgrade

2018-08-31 seekingalpha - 2
Acquiring MedReleaf was a significant upgrade for Aurora, in our opinion, both in terms of production capabilities and market position in Ontario.
ACB ACBFF NVS APHQF CMMDF MEDFF TLRY

3
Aurora Cannabis Seems Very Expensive

2018-08-28 seekingalpha
The company has recently increased the amount of facilities thanks to the acquisition of other operators.
ACB APH ACBFF WEED APHQF MEDFF CMMDF CGC

105
Why Aurora Cannabis' Acquisition Strategy Will Benefit Shareholders

2018-07-06 seekingalpha - 6
What the benefits of its acquisitions are for the company, and why I believe they'll pay off for shareholders.
STZ.B TWMJF ACB ACBFF WEED STZ CMMDF CGC

18
With Cannabis Sales To Start Soon, Aurora Cannabis Is A Play You Need To Know

2018-06-19 seekingalpha
ACBFF is a giant with the size rivaling that of CGC, yet it comes with much less fanfare.
TWMJF ACB ACBFF WEED CMMDF CGC

36
Which Marijuana Stocks Will Benefit From Canada's Next Move?

2018-05-30 seekingalpha - 1
Canada is likely to legalize recreational marijuana this summer, which could be a big catalyst for cannabis stocks in general, more specifically Canadian marijuana stocks.
STZ.B ACBFF STZ CMMDF CGC MT TWMJF ACB IIPR WEED APHQF MQTRF MEDFF

 
CannTrust Is A Prime Takeout Target For New Cannabis Entrants

2018-04-24 seekingalpha
Current capacity of 2,500 kg/annual is expected to reach 42,500 kg/annual once all expansions are completed.
CNTTF CMMDF

11
Did Aurora Overpay For CanniMed?

2018-03-16 seekingalpha
On March 9, Aurora Cannabis (OTCQB: ACBFF) announced that it has successfully completed its acquisition of CanniMed (OTC:CMMDF). The announcement stated that 70.66% of the outstanding shares have been tendered and all other conditions have been met under the offer. Aurora also announced that it will issue a total of approximately 50.6 million Aurora common shares and pay a total of approximately $98 million in cash for the CanniMed Shares tendered as of March 8, 2018.
ACB ACBFF APHQF CMMDF

33
Marijuana Stocks And Industry Drivers For 2018

2018-03-14 seekingalpha - 1
I believe that this year we will see industry drivers related to capital raises and M&A.
STZ.B TWMJF ATTBF ACB ACBFF WEED STZ CMMDF MEDFF ETN ATT

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...